Form 4: Olema CMO Exercises Options, Sells Shares

Olema Pharmaceuticals' Chief Medical Officer, Naseem Zojwalla, exercised stock options and subsequently sold a significant number of shares in late December 2025 under a pre-arranged trading plan.

Summary

• Naseem Zojwalla, Chief Medical Officer of Olema Pharmaceuticals, engaged in a series of stock option exercises and subsequent share sales between December 19 and December 23, 2025.
• A total of 140,000 stock options were exercised at prices of $15.25 and $7.02 per share.
• A total of 269,509 shares of common stock were sold at weighted average prices ranging from $27.66 to $28.93 per share.
• All reported transactions were conducted pursuant to a Rule 10b5-1 pre-arranged trading plan.
• The reporting person's direct beneficial ownership of common stock decreased from 133,997 shares (prior to the first reported transaction on December 19, 2025) to 4,488 shares following these transactions.

Sentiment

Score: 5

Explanation: The transactions, while involving significant insider selling, were conducted under a pre-arranged 10b5-1 plan, which mitigates the negative signal typically associated with discretionary insider sales. It reflects routine executive compensation management and diversification.

Positives

• The Chief Medical Officer exercised a substantial number of stock options (140,000 shares), indicating a realization of value from previously granted equity compensation.
• The exercise prices of $15.25 and $7.02 were significantly lower than the sale prices, demonstrating a profitable transaction for the insider.

Negatives

• The Chief Medical Officer sold a significant number of shares (269,509 shares), resulting in a substantial reduction of direct beneficial ownership from 133,997 shares to 4,488 shares.
• While conducted under a 10b5-1 plan, a large volume of insider selling can sometimes be perceived negatively by the market, suggesting a desire for diversification rather than increased conviction in the company's immediate future.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may interpret the significant reduction in direct beneficial ownership by a key executive as a potential signal, though the 10b5-1 plan context suggests it's for personal financial management rather than a lack of confidence in the company.

Key Dates

Recommendation

While the Chief Medical Officer's transactions involved a substantial sale of shares, they were executed under a pre-arranged 10b5-1 trading plan, which suggests the sales were for personal financial planning or diversification rather than a reaction to new, adverse company-specific information. A Form 4 filing primarily reports insider transactions and does not provide sufficient fundamental information to alter a long-term investment thesis. Investors should consider these transactions as a routine part of executive compensation management rather than a strong buy or sell signal, thus maintaining a 'hold' position based solely on this filing.

Keywords

Olema Pharmaceuticals, OLMA, Insider Trading, Stock Options, Share Sale, Executive Compensation, Form 4, Rule 10b5-1